MedPath

Age and Refraction in Predicting Myopia Progression in COVID-19

Completed
Conditions
Refraction Error
Myopia
Registration Number
NCT05305274
Lead Sponsor
Tianjin Eye Hospital
Brief Summary

To determine the longitudinal changes of age and refraction in predicting myopia progression with risk under the coronavirus disease 2019 (COVID-19) pandemic in a 3-year follow-up of a Chinese cohort.

Detailed Description

This was part of the large-scale Tianjin Eye Study, a population-based cohort study that longitudinally investigates the relationship between the age, refraction, and development of childhood RE in Tianjin, China.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34400
Inclusion Criteria
  • no concurrent eye disease;
  • age 6-15 years.
Exclusion Criteria
  • significant systemic illnesses
  • ocular conditions that could affect the corneal curvature, including congenital corneal diseases,
  • pterygium, keratoconus, other corneal degeneration or dystrophy conditions,
  • media opacity, uveitis, glaucoma
  • a history of intraocular surgery, refractive surgery,
  • neurologic or retinal diseases, current corneal refractive therapy (ortho-K),
  • low-dose atropine therapy for myopia control

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
changes of spherechange from baseline at 36 months

changes of sphere

changes of spherical equivalentchange from baseline at 36 months

changes of spherical equivalent

changes and distribution of visual acuitychange from baseline at 36 months

changes and distribution of visual acuity

changes of cylinderchange from baseline at 36 months

changes of cylinder

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Tianjin Eye Hospital

🇨🇳

Tianjin, China

Tianjin Eye Hospital
🇨🇳Tianjin, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.